About News News Subscribe Economics Health Policy Facet Area of Focus - News Ian H. Solomon Craig Volden Christine Mahoney Gerald Warburg Brian N. Williams Jay Shimshack Philip Potter David Leblang Kirsten Gelsdorf John Holbein Benjamin Castleman Lucy Bassett Gabrielle Adams Raymond C. Scheppach Timothy L. Davis Andrew S. Pennock Daphna Bassok Allan Stam Bala Mulloth Jill Rockwell Sophie Trawalter Jeanine Braithwaite Paul S. Martin Steve Hiss Laura Toscano Michael D. Williams Noah Myung Sebastian Tello-Trillo Benjamin Converse Brooke Lehmann Harry Harding Jeff Chidester Margaret Foster Riley Peter Johannessen Todd S. Sechser William Shobe Adam Leive Brad Carson Eileen Chou Frederick P. Hitz Galen Fountain James H. Wyckoff Jazmin Brown-Iannuzzi Jennifer Lawless Larry Terry Michele Claibourn Sally Hudson Adam Roux Amanda Crombie Andy Ortiz Brendan J. Boler Brooke Ray Daniel W. Player Diane Biesecker Diane Biesecker George Foresman Isaac Mbiti Jieun Pai Kimberly Jenkins Robinson Melissa Thomas-Hunt Michele Claibourn Molly Lipscomb Pam Cipriano Paul Becker Sarah Turner (-) Christopher J. Ruhm Facet People - News Facet UVA Partner - News Research and Commentary Facet News Type - News May 17, 2021 How to target opioid funding to states that need it most Health Policy Economics According to new research from Batten’s Christopher J. Ruhm, the federal government’s opioid grant funding structure favors the least populous states, which are not always the states with greatest need. In an op-ed for The Hill, Ruhm suggests several ways to improve the targeting of federal grants that aim to assist states with opioid problems. Read in The Hill May 03, 2021 Federal Opioid Grant Funding Favors Least Populous States, Not Those With the Greatest Need Economics Health Policy In a new paper published in the journal Health Affairs, Batten’s Christopher J. Ruhm and co-author Bradley A. Katcher find that the federal government’s opioid grant funding structure favors the least populous states, which are not always the states with greatest need. Learn more Apr 09, 2020 How Might the COVID-19 Recession Affect Your Health? An Economist Explains. Economics Health Policy Recessions may be good for overall physical health, but this one could be different. Batten professor Chris Ruhm presented an online talk Wednesday offering an economist’s view of the overall health effects of the COVID-19 recession. His talk was the school’s third installment of its expert chat series about COVID-19. Learn more Nov 21, 2019 New Research: Non-Opioid Drug Death Rates Are Also on the Rise Economics The number of Americans dying from drug overdoses has risen rapidly in the last decade, with opioids viewed as the primary culprit. However, recent research suggests that opioids are not the only drug involved. According to Batten professor of economics, Christopher J. Ruhm, half of the overdose deaths have involved polydrug use and deaths involving nonopioid drugs are rising almost as fast as those involving opioids. READ IN UVA TODAY Stay Up To Date with the Latest Batten News and Events Subscribe
May 17, 2021 How to target opioid funding to states that need it most Health Policy Economics According to new research from Batten’s Christopher J. Ruhm, the federal government’s opioid grant funding structure favors the least populous states, which are not always the states with greatest need. In an op-ed for The Hill, Ruhm suggests several ways to improve the targeting of federal grants that aim to assist states with opioid problems. Read in The Hill
May 03, 2021 Federal Opioid Grant Funding Favors Least Populous States, Not Those With the Greatest Need Economics Health Policy In a new paper published in the journal Health Affairs, Batten’s Christopher J. Ruhm and co-author Bradley A. Katcher find that the federal government’s opioid grant funding structure favors the least populous states, which are not always the states with greatest need. Learn more
Apr 09, 2020 How Might the COVID-19 Recession Affect Your Health? An Economist Explains. Economics Health Policy Recessions may be good for overall physical health, but this one could be different. Batten professor Chris Ruhm presented an online talk Wednesday offering an economist’s view of the overall health effects of the COVID-19 recession. His talk was the school’s third installment of its expert chat series about COVID-19. Learn more
Nov 21, 2019 New Research: Non-Opioid Drug Death Rates Are Also on the Rise Economics The number of Americans dying from drug overdoses has risen rapidly in the last decade, with opioids viewed as the primary culprit. However, recent research suggests that opioids are not the only drug involved. According to Batten professor of economics, Christopher J. Ruhm, half of the overdose deaths have involved polydrug use and deaths involving nonopioid drugs are rising almost as fast as those involving opioids. READ IN UVA TODAY